FierceBiotech 2025-12-17 Norgine gets in on Vir's hepatitis D program with €550 European licensing pact
FierceBiotech 2025-12-17 Fired NIH institute director sues Trump health officials, seeks reinstatement and backpay
FierceBiotech 2025-12-17 Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst
FierceBiotech 2025-12-17 Addition Tx does the math and emerges from stealth with $100M, biotech vets on exec team
FierceBiotech 2025-12-17 Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B
FierceBiotech 2025-12-17 Medtronic rolls out new peripheral thrombectomy system while making advances in brain bleeds
FierceBiotech 2025-12-17 Nektar claims phase 2 alopecia success after excluding patients who ‘should never have been enrolled’
FierceBiotech 2025-12-16 December deal flurry rolls on with Genentech-Caris cancer collab worth up to $1.1B
FierceBiotech 2025-12-16 Xoma acquires another struggling biotech, this time zeroing in on Generation Bio
FierceBiotech 2025-12-16 Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says
FierceBiotech 2025-12-16 Ramaswamy-backed Ambros Therapeutics launches with $125M to develop pain drug
FierceBiotech 2025-12-16 Sanofi signs $1B biobucks pact for Alzheimer’s asset in 2nd biotech deal of the day